Connect Biopharma Holdings Limited (CNTB) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 4 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for CNTB is $9.00, representing a +195.1% upside from the current price of $3.05. Price targets range from a low of $9.00 to a high of $9.00.
